Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus HALDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE INTENSOL versus HALDOL.
CHLORPROMAZINE HYDROCHLORIDE INTENSOL vs HALDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpromazine is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits antagonism at serotonin 5-HT2, histamine H1, alpha-1 adrenergic, and muscarinic receptors, contributing to its sedative, antiemetic, and hypotensive effects.
Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia. It also has moderate affinity for sigma receptors and weak affinity for serotonin 5-HT2, alpha-adrenergic, and histamine H1 receptors.
Oral: 25-50 mg 2-3 times daily, up to 1000 mg/day in severe psychosis. IM: 25-50 mg every 1-4 hours until controlled, then switch to oral.
Initial: 1-5 mg PO/IM twice daily; titrate up to 5-10 mg/day. Acute agitation: 5-10 mg IM every 1-8 hours. Maintenance: 5-10 mg/day PO/IM. Maximum: 100 mg/day.
None Documented
None Documented
15-30 hours; prolonged in elderly and hepatic impairment; active metabolites (e.g., 7-hydroxychlorpromazine) have longer half-lives (up to 12-24 hours)
Terminal elimination half-life is approximately 21 hours (range 12–37 hours). Extended half-life in chronic administration supports once-daily dosing; dose adjustments required in hepatic impairment.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (~20-30%)
Renal (approximately 40%, with 1% unchanged; remainder as metabolites) and fecal (approximately 60%, primarily via bile).
Category C
Category C
Antipsychotic
Antipsychotic